FGFR2 gene fusions are most frequent in cholangiocarcinoma, and are also detected, albeit less commonly, in colorectal cancer, hepatocarcinoma and NSCLC (22). This evidence concerns the gene FGFR2 and non-small cell lung carcinoma.